33 results on '"Ferzi, A."'
Search Results
2. Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer: insights from real-world data of a nationwide cohort
3. Abstract P1-11-04: Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort
4. 270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort
5. Strategi Pengembangan Taman Marga Satwa dan Budaya Kinantan (TMSBK) studi kasus Benteng Fort de Kock Dinas Pariwisata, Pemuda dan Olahraga kota Bukittinggi
6. 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer
7. Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study
8. Why Do Outsourcing Employees Have High Engagement? An Evidence of the Cause and Its Consequences
9. 95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)
10. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
11. Abstract P6-18-28: Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive (HR+)/HER2 receptor-negative (HER2-) metastatic breast cancer (MBC): A real life multicenter Italian study
12. Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
13. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
14. Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials
15. Comorbidity scores as predictive tools for nivolumab toxicity in patients with advanced non small cell lung cancer (NSCLC): preliminary results of a prospective multicenter study
16. A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer
17. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
18. Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study
19. Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
20. Patterns of treatment and outcome of fulvestrant 500mg in postmenopausal women with hormone-positive (HR+)/Her2-negative (HER2-) metastatic breast cancer (MBC): a real life multicenter Italian experience
21. Beyond clinical trials: a real life multicenter Italian experience on Fulvestrant 500mg in postmenopausal women with hormone-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC)
22. PO64 METRONOMIC CHEMOTHERAPY (CHT) COMBINATION OF VINORELBINE (VRL) AND CAPECITABINE (CAPE) IN HER2- ADVANCED BREAST CANCER (ABC) PATIENTS (PTS) DOES NOT IMPAIR GLOBAL QOL. FIRST RESULTS OF THE VICTOR-2 STUDY
23. Albumin-bounded Paclitaxel (nab-Paclitaxel) in metastatic breast cancer: new insights from a real life multicenter Italian experience
24. 1872 Moving beyond clinical trials: A real word multicenter Italian experience with albumin-bounded Paclitaxel (nab-Paclitaxel) in metastatic breast cancer
25. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
26. Targeted Chemotherapy with Albumin-Bound Paclitaxel (Nab-Paclitaxel) for Metastatic Breast Cancer (Mbc): Which Benefit for Which Patients? a Real World Multicenter Italian Experience on 150 Women
27. Efficacy of Trastuzumab in Unselected Patients with HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis
28. PO62 DIFFERENT PATTERNS OF TREATMENT WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR TARGETED CHEMOTHERAPY IN METASTATIC BREAST CANCER: A MULTICENTER ITALIAN EXPERIENCE ON 125 WOMEN
29. Natural history of malignant bone disease in non-small cell lung cancer: Preliminary results of a multicenter bone metastasis survey.
30. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer
31. First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study.
32. Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
33. Seasonal Analysis of Zoobenthos Associated with a Zostera marina L. Bed in Gulbahce Bay Aegean Sea, Turkey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.